NO20060144L - Nye modifiserte corinmolekyler som har substituerte aktiveringssekvenser og anvendelser derav - Google Patents
Nye modifiserte corinmolekyler som har substituerte aktiveringssekvenser og anvendelser deravInfo
- Publication number
- NO20060144L NO20060144L NO20060144A NO20060144A NO20060144L NO 20060144 L NO20060144 L NO 20060144L NO 20060144 A NO20060144 A NO 20060144A NO 20060144 A NO20060144 A NO 20060144A NO 20060144 L NO20060144 L NO 20060144L
- Authority
- NO
- Norway
- Prior art keywords
- molecules
- corin molecules
- substituted
- new modified
- activation sequences
- Prior art date
Links
- 102100037293 Atrial natriuretic peptide-converting enzyme Human genes 0.000 title abstract 5
- 101710133555 Atrial natriuretic peptide-converting enzyme Proteins 0.000 title abstract 5
- 230000004913 activation Effects 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical class O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000005714 functional activity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Denne oppfinnelsen vedrører nye modifiserte corinmolekyler, eller fiiagmenter eller derivater derav, som omfatter en substituert aktiveringssekvens. De modifiserte corinmolekylene blir kløyvet på den substituerte aktiveringssekvensen, for derved å generere aktiverte corinmolekyler, eller fragmenter eller derivater derav, som oppviser den fimksjonelle aktiviteten til naturlig forekommende villtype- corinmolekyler. De modifiserte corinmolekylene kan bli benyttet til å behandle en mengde sykdommer eller forstyrrelser, inkludert kongestiv hjertesvikt og akutt hjerteinfarkt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47768303P | 2003-06-11 | 2003-06-11 | |
| PCT/US2004/018669 WO2004111225A1 (en) | 2003-06-11 | 2004-06-09 | Novel modified corin molecules having substitute activation sequences and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20060144L true NO20060144L (no) | 2006-01-10 |
Family
ID=33551745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060144A NO20060144L (no) | 2003-06-11 | 2006-01-10 | Nye modifiserte corinmolekyler som har substituerte aktiveringssekvenser og anvendelser derav |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7176013B2 (no) |
| EP (1) | EP1636356A1 (no) |
| JP (1) | JP2007502132A (no) |
| KR (1) | KR20060022683A (no) |
| CN (2) | CN1836037A (no) |
| AU (1) | AU2004248192A1 (no) |
| BR (1) | BRPI0411353A (no) |
| CA (1) | CA2527361A1 (no) |
| IL (1) | IL172095A0 (no) |
| MX (1) | MXPA05013321A (no) |
| NO (1) | NO20060144L (no) |
| PL (1) | PL379196A1 (no) |
| RU (1) | RU2006100035A (no) |
| WO (1) | WO2004111225A1 (no) |
| ZA (1) | ZA200600224B (no) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050026255A1 (en) * | 2002-06-25 | 2005-02-03 | Morser John Michael | Corin, a serine protease |
| TW200723151A (en) * | 2005-12-07 | 2007-06-16 | Era Digital Media Co | Business website method |
| US20110160128A1 (en) * | 2008-03-28 | 2011-06-30 | Qingyu Wu | Corin for Treating Obesity and Diabetes |
| WO2010096658A1 (en) | 2009-02-19 | 2010-08-26 | The Cleveland Clinic Foundation | Corin as a marker for heart failure |
| US10314894B2 (en) * | 2014-02-12 | 2019-06-11 | The Cleveland Clinic Foundation | Treatment of cardio-renal disease using PCSK6 |
| SG10202001578RA (en) * | 2016-02-29 | 2020-04-29 | Regeneron Pharma | Rodents having a humanized tmprss gene |
| CN105734070A (zh) * | 2016-04-11 | 2016-07-06 | 苏州大学 | Corin基因变异体及其用途 |
| CN108066286B (zh) * | 2016-11-10 | 2021-06-29 | 复旦大学 | 炔丙基半胱氨酸纳米粒长循环脂质体及其制备方法和用途 |
| CN118530307B (zh) * | 2024-06-14 | 2025-09-09 | 中国人民解放军军事科学院军事医学研究院 | 一种阻断pts途径的多肽及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK275788A (da) * | 1987-05-22 | 1989-02-03 | Zymogenetics Inc | Fibrinolytiske proteiner |
| US5869637A (en) | 1996-07-22 | 1999-02-09 | Incyte Pharmaceuticals, Inc. | Human Kallikrein |
| US5968782A (en) * | 1996-12-04 | 1999-10-19 | Brigham And Womens's Hospital, Inc. | Mast cell protease that cleaves fibrinogen |
| WO1998036054A1 (en) | 1997-02-13 | 1998-08-20 | Amrad Operations Pty. Ltd. | Novel molecules |
| AU9260598A (en) | 1997-08-22 | 1999-03-16 | Boehringer Mannheim Gmbh | Zymogenic protease precursors that can be autocatalytically activated and their use |
| EP0927764B1 (de) * | 1997-12-03 | 2004-05-26 | Boehringer Mannheim Gmbh | Chimäre Serinproteasen |
| ES2307338T3 (es) | 1998-06-05 | 2008-11-16 | Bayer Schering Pharma Aktiengesellschaft | Corina, una serina proteasa. |
| US6420157B1 (en) * | 1999-04-30 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Zymogen activation system |
| EP1252300B1 (en) | 2000-02-03 | 2011-01-19 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| EP1326882A2 (en) * | 2000-06-19 | 2003-07-16 | Dyax Corp. | Enterokinase cleavage sequences and their use |
| HUP0203251A2 (hu) * | 2000-09-04 | 2003-01-28 | Hyo-Joon Kim | Az apolipoprotein B-100 epitópját utánzó peptidek, ezeknek megfelelő konkatemér és módosított peptidek és ezeket tartalmazó vakcinakészítmények |
| FR2831170B1 (fr) * | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
| WO2004033630A2 (en) * | 2002-10-04 | 2004-04-22 | Schering Aktiengesellschaft | Modified hepsin molecules having a substitute activation sequence and uses thereof |
-
2004
- 2004-06-09 CA CA002527361A patent/CA2527361A1/en not_active Abandoned
- 2004-06-09 KR KR1020057023612A patent/KR20060022683A/ko not_active Withdrawn
- 2004-06-09 CN CNA2004800230099A patent/CN1836037A/zh active Pending
- 2004-06-09 RU RU2006100035/13A patent/RU2006100035A/ru not_active Application Discontinuation
- 2004-06-09 CN CNA2007101280546A patent/CN101109011A/zh active Pending
- 2004-06-09 BR BRPI0411353-5A patent/BRPI0411353A/pt not_active IP Right Cessation
- 2004-06-09 MX MXPA05013321A patent/MXPA05013321A/es not_active Application Discontinuation
- 2004-06-09 PL PL379196A patent/PL379196A1/pl not_active Application Discontinuation
- 2004-06-09 JP JP2006533746A patent/JP2007502132A/ja active Pending
- 2004-06-09 WO PCT/US2004/018669 patent/WO2004111225A1/en not_active Ceased
- 2004-06-09 US US10/865,978 patent/US7176013B2/en not_active Expired - Fee Related
- 2004-06-09 AU AU2004248192A patent/AU2004248192A1/en not_active Abandoned
- 2004-06-09 EP EP04755046A patent/EP1636356A1/en not_active Withdrawn
-
2005
- 2005-11-22 IL IL172095A patent/IL172095A0/en unknown
-
2006
- 2006-01-10 ZA ZA200600224A patent/ZA200600224B/en unknown
- 2006-01-10 NO NO20060144A patent/NO20060144L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004248192A1 (en) | 2004-12-23 |
| CN1836037A (zh) | 2006-09-20 |
| CN101109011A (zh) | 2008-01-23 |
| IL172095A0 (en) | 2009-02-11 |
| EP1636356A1 (en) | 2006-03-22 |
| KR20060022683A (ko) | 2006-03-10 |
| CA2527361A1 (en) | 2004-12-23 |
| RU2006100035A (ru) | 2006-08-27 |
| US20050003416A1 (en) | 2005-01-06 |
| WO2004111225A1 (en) | 2004-12-23 |
| US7176013B2 (en) | 2007-02-13 |
| ZA200600224B (en) | 2007-04-25 |
| JP2007502132A (ja) | 2007-02-08 |
| PL379196A1 (pl) | 2006-07-24 |
| BRPI0411353A (pt) | 2006-07-11 |
| MXPA05013321A (es) | 2006-03-09 |
| WO2004111225A8 (en) | 2006-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20080745L (no) | Nye peptider for anvendelse i behandling av fedme | |
| EA200702346A1 (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| SI2336359T1 (sl) | 1L1RL-1 kot marker kardiovaskularne bolezni | |
| NO20060144L (no) | Nye modifiserte corinmolekyler som har substituerte aktiveringssekvenser og anvendelser derav | |
| NO20070081L (no) | Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer | |
| EA200301232A1 (ru) | Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы | |
| NO20092651L (no) | Dihydropyridinderivater som er anvendelige som proteinkinaseinhibitorer | |
| CY1107871T1 (el) | Παραγωγα πυριμιδινης και η χρηση τους ως ρυθμιστων cb2 | |
| CY1108655T1 (el) | ΘΕΙΟΖΟΛΙΔΙΝ-4-ΟΝΕΣ ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΠΡΩΤΕΪΝΩΝ hYAK3 | |
| EP1605752A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS | |
| DE60137501D1 (de) | Optisches abbildungssystem zur darstellung der genexpression des gesamten körpers und anwendungen | |
| EA200601074A1 (ru) | Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли) | |
| EA200801462A1 (ru) | Связывающий днк-сайт активатора транскрипции, пригодный для экспрессии генов | |
| NO20081014L (no) | Sammensetninger | |
| DE502007005857D1 (de) | Isoliertes naturidentisches kollagen | |
| BRPI0508350A (pt) | métodos para interferir com fibrose | |
| DE602005008412D1 (de) | Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen | |
| EP1509251A4 (en) | NUCLEIC ACIDS, POLYPEPTIDES, AND METHODS FOR MODULATING APOPTOSIS | |
| NO20082410L (no) | Biomarkorer for anti-nogo-a antistoffbehandling ved spinalstrengskader | |
| NO20070780L (no) | Celloverflateprotein. | |
| EA200400438A1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной гипертонии | |
| ATE482976T1 (de) | Defensinproteine | |
| NO20055210L (no) | Inhibitorproteiner av en protease og anvendelse derav | |
| DK1664102T3 (da) | Isoleret photoprotein mtclytin, samt dets anvendelse | |
| WO2007017154A3 (en) | Human inhibitory anti-factor viii antibodies binding to the a2 domain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |